-1.33%
Today
Loading 1D prices…
Company profile
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Norwood, MA, United States
Employees
36
Fiscal year end
1231
CIK
1595097
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| LFCRLifecore Biomedical Inc. Common Stock | $156M | $128.9M | -30.04% | -$1.27 | +0.73% | Buy |
| IMUXImmunic Inc. Common Stock | $155.8M | $0.00 | — | -$0.62 | -3.55% | Buy |
| SPRBSpruce Biosciences Inc. Common Stock | $154.3M | $0.00 | — | -$50.83 | -1.20% | Buy |
| OGIOrganigram Global Inc. Common Shares | $151.4M | — | — | -$0.194 | -1.87% | Buy |
| MENSJyong Biotech Ltd. Ordinary Shares | $151.3M | $0.00 | — | -$0.06 | -1.00% | Unrated |